Fundamental Data for MATK

MARTEK BIO(NSDQ:MATK)

Martek Biosciences Corp. develops, manufactures and sells products from microalgae. The company''s products include: (1) specialty, nutritional oils for infant formula, nutritional supplements and food ingredients; (2) high value reagents and technologies to visualize molecular interactions for drug discovery and development; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection. (Company Press Release)

# Employees: 569

Address: 6480 Dobbin Road,Columbia,MD,USA

Phone: 410 740-0081

Fax: 410 740-2985

Website: www.martekbio.com

Email: investors@martek.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

David M. Abramson (Presi.)

Steve Dubin (C.E.O.; Dir.)

David M. Feitel (Sr. V.P.; Genl. Counsel)

Tim Fealey Ph.D (Sr. V.P.; Chief Innovation Off.)

Barney B. Easterling (Sr. V.P.; Manufacturing,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 7/31/2009

Next Earnings Date(Expected): 12/10/2009

Mean EPS (Next Qtr): $0.31

Mean EPS (Year): $1.40

Mean Estimate(Long Term): $10.00

P/E Ratio(Based on EPS estimate): 12.940

Number of Estimates: 6

Shares Performance

Period	MATK	Compare to S&P
YTD	-40.25 %	-50.55 %
4 Weeks	-5.28 %	-6.30 %
12 Weeks	-27.24 %	-31.40 %

Shares Information

Analyst Coverage: Y

Avg Volume: 328329

Shares Outstanding: 33M

Market Cap: $0.60B

52 Week High: $30.88

52 Week Low: $15.60

P/E Ratio: 15.610

PEG Ratio: 1.290

Split: On 1/1/1990 MATK split by factor of 0.250

Earnings Performance

EPS Growth in Last Quarter: -18.18 %

EPS Growth in Last Year: -3.57 %

Sales Growth in Last Quarter: -15.77 %

Sales Growth in Last Quarter: -11.96 %

Financials

Qtr Book Value: $0.97

Cash Flow/Share: $9.05

Change in Payout Ratio: -0.010

Price/Sales: -0.010